Repaglinide
+ Metformin Vs. Nateglinide + Metformin in Treating
Type 2 Diabetes
Patients with type 2 diabetes have significantly
better fasting plasma glucose levels (FPG) and
hemoglobin A1c (HbA1c) levels when treated with
metformin combined with repaglinide rather than
combined with nateglinide.
Philip
Raskin, MD, professor of internal medicine, University
of Texas Southwestern at Dallas, Tex, presented
these findings here on May 16th during the American
Association of Clinical Endocrinologists 12th
Annual Meeting and Clinical Congress.
The
parallel group, randomized, open-label trial,
compared the efficacy and safety of repaglinide
and nateglinide in combination with metformin
for 16 weeks. The group enrolled 192 type 2 diabetic
patients with mean ages of 55.9 and 45.3 respectively.
Mean
change from baseline HbA1c in the repaglinide
patients was –1.28 (P<0.001), almost
double the –0.67 (P<0.001) mean change
in the nateglinide group. FPG baseline mean for
the repaglinide group was 189 compared to 191
for the nateglinide group. The mean change from
those baselines was –31 for the repaglinide
group compared to –21 for the nateglinide
group.
"This
research may help clinicians decide which of these
short acting nonsulfonylurea secretagogues to
use in combination with metformin after failure
of single oral-agent monotherapy," said Dr.
Raskin.
This
study was financed by Novo Nordisk Pharmaceuticals,
Inc., Princeton, N.J.
[Study
title: Efficacy and Safety of Combination Therapy:
Repaglinide Plus Metformin Versus Nateglinide
Plus Metformin. Abstract 46]
